Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption. 1976

D J Greenblatt, and R I Shader, and J S Harmatz, and K Franke, and J Koch-Weser

Ten healthy male subjects ingested 25 mg of chlordiazepoxide hydrochloride (Librium) with 100 ml of water or with 100 ml of magnesium and aluminum hydroxide (Maalox) in a single-dose crossover study. Multiple venous blood samples drawn during the first 24 hr after each dose were assayed for concentrations of chlordiazepoxide and its major metabolite, desmethylchlordiazepoxide. The antacid prolonged the mean chlordiazepoxide absorption half-time from 11 to 24 min, and in 6 of 10 subjects delayed achievement of the peak blood concentration by from 0.5 to 3.0 hrs. The formation of desmethylclordiazepoxide was also slowed. The areas under the 24 hr blood concentration curve for chlordiazepoxide and for its metabolite were not influenced by the antacid. The apparent elimination half-life of chlordiazepoxide (8.4 and 8.2 hr) was not significantly affected. Administration of chlordiazepoxide with antacid reduces the rate of its absorption but does not alter the completeness of absorption or the apparent rate of elimination.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008274 Magnesium A metallic element that has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. It is important for the activity of many enzymes, especially those involved in OXIDATIVE PHOSPHORYLATION.
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D002707 Chlordiazepoxide An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. Methaminodiazepoxide,7-Chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepine-4-oxide,7-Chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide,Chlordiazepoxide Hydrobromide,Chlordiazepoxide Hydrochloride,Chlordiazepoxide Monohydrochloride,Chlordiazepoxide Perchlorate,Chlozepid,Elenium,Librium,7 Chloro 2 methylamino 5 phenyl 3H 1,4 benzodiazepine 4 oxide,7 Chloro N methyl 5 phenyl 3H 1,4 benzodiazepin 2 amine 4 oxide,Hydrobromide, Chlordiazepoxide,Hydrochloride, Chlordiazepoxide,Monohydrochloride, Chlordiazepoxide,Perchlorate, Chlordiazepoxide
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006878 Hydroxides Inorganic compounds that contain the OH- group.

Related Publications

D J Greenblatt, and R I Shader, and J S Harmatz, and K Franke, and J Koch-Weser
March 2016, Pulmonary circulation,
D J Greenblatt, and R I Shader, and J S Harmatz, and K Franke, and J Koch-Weser
October 1993, Antimicrobial agents and chemotherapy,
D J Greenblatt, and R I Shader, and J S Harmatz, and K Franke, and J Koch-Weser
July 1973, Schweizerische medizinische Wochenschrift,
D J Greenblatt, and R I Shader, and J S Harmatz, and K Franke, and J Koch-Weser
August 1976, The Journal of the Arkansas Medical Society,
D J Greenblatt, and R I Shader, and J S Harmatz, and K Franke, and J Koch-Weser
May 1979, British journal of clinical pharmacology,
D J Greenblatt, and R I Shader, and J S Harmatz, and K Franke, and J Koch-Weser
January 1981, Journal of clinical pharmacology,
D J Greenblatt, and R I Shader, and J S Harmatz, and K Franke, and J Koch-Weser
November 1982, American journal of hospital pharmacy,
D J Greenblatt, and R I Shader, and J S Harmatz, and K Franke, and J Koch-Weser
December 1991, Minerva pediatrica,
D J Greenblatt, and R I Shader, and J S Harmatz, and K Franke, and J Koch-Weser
July 1988, Annals of internal medicine,
D J Greenblatt, and R I Shader, and J S Harmatz, and K Franke, and J Koch-Weser
March 1990, DICP : the annals of pharmacotherapy,
Copied contents to your clipboard!